Around the world
In 2004, TTY decided to activate the establishment of various internationalized capabilities in European market for the strategic goal of internationalization. TTY started its cultivating plan in European market. Through years of effort in European market, from drug development, examination, and registration to strategic marketing, TTY obtained extensive achievement with stable and strong strategic partners. In March 2009, all items of TTY Chungli factory passed the EU inspection. TTY Chungli factory became the first factory with EU verification in Taiwan. Later, in August, TTY and Netherlands to – BBB, a Pharmaceutical company, activated the co-development of brain-targeted drug, Liposomal Doxorubicin. In September, TTY obtained the first permit license of the anticancer generic drug, Docetaxel in Europe. Docetaxel was officially launched in Europe at the end of 2010. With the successful acquirement of the Docetaxel permit license in Europe, TTY accelerated its cooperation with its local strategic partners in Germany to enter the EU markets to acquire drug permit license from EU member countries. On top of its achievement in EU, TTY will focus on American markets at the next stage.
In 2005, TTY established department of international business development, actively building its global sales network. Today, TTY promotes its pharmaceutical products beyond Taiwan. TTY successfully marketing its self-developed products to various countries in the world, including China, Singapore, Malaysia, Vietnam, Thailand, Philippines, Sri Lanka, India, Pakistan, Russia, South Africa, Zimbabwe, Nigeria, and Malawi. In addition, TTY has established dealer distribution networks in more than 50 countries in Asia, Europe, Africa, America, and Oceania.
In 2010, TTY kept its development in Chinese market, and set a new office in Hanoi, Vietnam, activating cultivating plan in Asian markets of the next stage. TTY Asia Platform (TAP) was founded for dedication of building TTY as the best partner for major international pharmaceutical company and expert of development, clinical practices, regulation, and marketing in Asia. Since 2011, TTY had founded various locations for drug development and distribution in Korea and Hong Kong. TTY also extended its cultivation efforts to Singapore, Malaysia, Taiwan, China, Hong Kong, and Korea, concurrently building a comprehensive platform for clinical trials in Asia.
This extensive international achievement brings TTY influences beyond Taiwan. TTY broke through the environmental restrictions with cultivation in Asian markets, integration of drug development in Europe, US, and Japan, and global marketing advantages. TTY are capable to handle various tasks from new drug evaluation, prescription design, pre-clinical trial, clinical trial, strategies, regulations, production with international quality, to build global distribution arrangement. TTY can face direct competition from international-class pharmaceutical companies. In the future, TTY is looking forward being the first original development pharmaceutical company in Asia, becoming the best strategic partner for international companies in their cultivation efforts of building technology platform and development in anti-cancer, cardiovascular, and post-anti infection disease areas to conduct global new drug development and operation plan.